COMMUNIQUÉS West-GlobeNewswire

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
26/03/2026
– Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe – Advances Proposed Expedited Regulatory Approval Pathways in [...]
Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
26/03/2026
OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary [...]
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
26/03/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in Acumen’s Enhanced [...]
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
26/03/2026
- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. - - He will work with the Company’s leadership team to expand corporate collaborations to [...]
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
26/03/2026
At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p<0.05) and total fat (-5%), stabilization of lean mass (+2 [...]
Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
26/03/2026
San Antonio Center Cleared to Commence Commercial Sales of Normal Source Plasma State of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue [...]
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026 Phase 2 IRIS trial for ML-004 for autism [...]
Preliminary results for the year ended 31 December 2025
26/03/2026
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved: Revenue [...]
HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
26/03/2026
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics NEW YORK and VIENNA, March 26, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “ [...]
Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability
26/03/2026
Preclinical findings show cytisinicline's minimal 5-HT3 serotonin receptor binding offers insight into observed low nausea rates in smoking and vaping cessation trials SEATTLE and VANCOUVER, British Columbia, March 26, [...]
Tilray Brands Announces Partnership with Popsicle® to Launch Popsicle Adult Beverages
26/03/2026
Iconic Popsicle® Flavors Reimagined as Ready-to-Drink Hard Beverages Through New Licensing Agreement NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: [...]
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
26/03/2026
Insurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage Concurrently, Vivos Implements Cost Reduction Initiatives Related to [...]
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
26/03/2026
Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and KOLs will discuss CUE-401, the company’s lead asset for the treatment of [...]
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
26/03/2026
According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers The Rain Foundation [...]
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
26/03/2026
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System
26/03/2026
World’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases performed using the LIBERTY System [...]
Notice convening the Annual General Meeting in BioPorto A/S
26/03/2026
26 March 2026 Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on [...]
Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026
26/03/2026
Oslo, 26 March 2026 - The Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 09:00 CEST on 23 April 2026. The General Meeting will be held electronically and all documents related to the [...]
FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428's Potential for Best-in-Class PARG Inhibition
26/03/2026
PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show high potency across multiple solid tumor cell lines and in vivo models, including those resistant [...]

Pages